Prevalence of claudin 18.2 (CLDN18.2) and the association of biomarkers with clinical activity in patients with gastric or gastroesophageal adenocarcinoma (G/GEJa) treated with zolbetuximab.-MedSci.cn

Prevalence of claudin 18.2 (CLDN18.2) and the association of biomarkers with clinical activity in patients with gastric or gastroesophageal adenocarcinoma (G/GEJa) treated with zolbetuximab.

Moran, DM; Guerrero, A; Ueno, Y; Park, JW; Pavese, J; Kaneko, Y; Matsangou, M; Shitara, K

JOURNAL OF CLINICAL ONCOLOGY, 2023; 41 (): 466

科室
- - 订阅+
  - 更多科室
工具
服务